Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bermekimab in Moderate to Severe Hidradenitis Suppurativa
NCT04019041Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2019
- Primary completion
- May 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bermekimab in hidradenitis suppurativa (HS), sponsored by Janssen Pharmaceutical. Started Sep 2019; status: completed.
02
Drugs
bermekimab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT04019041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04019041.